Axitinib

CHICAGO — In this Healio Video Perspective from the AAO meeting, David A. Eichenbaum, MD, discusses results from a phase 1 trial investigating axitinib for the treatment of neovascular age-related macular degeneration.

In this Healio Video Perspective from the ASRS meeting, Pravin U. Dugel, MD, of Ocular Therapeutix discusses the phase 3 program for Axpaxli, an axitinib implant for wet age-related macular degeneration.

MADRID — In this video, Toni Choueiri, MD, talked about “a very important study” from China in advanced renal cell carcinoma presented at ESMO Congress.

NASHVILLE, Tenn. — Patients with renal cell carcinoma who met eligibility criteria for pivotal phase 3 trials achieved significantly longer survival after combination immunotherapy than trial-ineligible patients, according to study results.

MADRID — Treatment with toripalimab plus axitinib resulted in significantly longer PFS than treatment with sunitinib in patients with previously untreated advanced kidney cancer, according to a presentation from ESMO Congress.

Pembrolizumab as adjuvant therapy significantly prolonged OS compared with placebo among adults with renal cell carcinoma who underwent nephrectomy with or without resection of metastatic lesions, according to the agent’s manufacturer.

SEATTLE — Suprachoroidal axitinib had an “excellent” safety profile at all doses in the treatment of wet age-related macular degeneration, with early signs of durability and reduction in treatment burden, a speaker said here.

A presentation at ASCO Annual Meeting supported the use of first-line axitinib and pembrolizumab in the treatment of patients with advanced renal cell carcinoma.

CHICAGO — Pembrolizumab plus axitinib continued to confer a survival benefit vs. sunitinib at 5-year follow-up as first-line therapy for patients with advanced clear cell renal cell carcinoma, according to study results.

CLS-AX demonstrated positive results in the phase 1/2a OASIS clinical trial in neovascular age-related macular degeneration, Clearside Biomedical announced in a press release.